However, pharmacological approaches for restoring Ca2+ spark–BK channel vasoregulation, together with restoration of Kir2.1-driven neurovascular coupling using PIP2-boosting approaches, may represent a strategy for targeting the two principal cerebrovascular deficits in AD: cerebral hypoperfusion and neurovascular uncoupling. This evidence concerns the gene KCNJ2 and Alzheimer disease.